日本人網膜静脈閉塞症患者におけるラニビズマブの有効性と安全性

基本情報

NCT ID

NCT01377597

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

47

治験依頼者名

Novartis

概要

The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein occlusion (BRVO or CRVO) to support the applicability of the phase III study results of BRAVO and CRUISE in this indication, in the Japanese ethnic patients.

対象疾患

介入

依頼者（Sponsor）